Dr. Sarah Fakih

Dr. Sarah Fakih, MBA, currently serves as Vice President of Corporate Communications and Investor Relations at CureVac, where notable achievements include leading investor relations activities during a successful Nasdaq IPO and managing communication strategies during a major company restructuring. Previously, Dr. Fakih held the position of Vice President of Investor Relations at MorphoSys AG, focusing on communication strategies for the company’s transformation to an integrated biopharma firm. Prior experience at QIAGEN encompassed various roles leading to a directorial position in Investor Relations, where Dr. Fakih cultivated strong relationships with global stakeholders and shaped corporate communication strategies. Dr. Fakih holds a degree in Bioinorganic/Medicinal Chemistry from the University of Münster, an MBA from the Julius Maximilians University of Würzburg, and has engaged in significant postdoctoral research at King's College London.